SS31 Ameliorates Sepsis-Induced Heart Injury by Inhibiting Oxidative Stress and Inflammation
Sepsis-induced myocardial dysfunction (SIMD), lack of effective treatment, accounts for high mortality of sepsis. Mitochondrion-targeted antioxidant peptide SS31 has been revealed to be responsible for certain cardiovascular disease by ameliorating oxidative stress injury. But whether it protects a septic heart remains little known. This study sought to prove that SS31 was capable of improving sepsis-induced myocardial dysfunction dramatically. C57BL/6 mice were intraperitoneally administered lipopolysaccharide (LPS), exposed to systemic inflammation. Thirty-five C57BL/6 mice were randomly divided into four groups: sham group, LPS group (5 mg/kg), SS31 group (5 mg/kg), and SS31 + LPS group (treatment group). Heart tissues were harvested for pathological examination at the indicated time points. H9C2 cell were treated with LPS with or without the presence of SS31 (10 μM) at 37 °C to assess the effect on cardiomyocytes at the indicated time points. SS31 restored myocardial morphological damage and suppressed inflammatory response as evidenced by significantly decreasing the mRNA levels of IL-6, IL-1β, and TNF-α in vitro and in vivo. In addition, myocardial energy deficiency secondary to sepsis was remarkedly ameliorated by SS31. Furthermore, we found that SS-31 normalized the activity of malondialdehyde, glutathione peroxidase, and superoxide dismutase in vitro and in vivo, and maintained mitochondrial membrane potential (MMP) as well. And western blot was applied to measure the expressions of p-p38MAPK, p-JNK1/2, p-ERK, p62, and NF-κB p65; the results illuminated that the cardioprotective effect of SS31 was partly linked to NF-κB. In conclusion, SS31 therapy effectively protected the heart against LPS-induced cardiac damage.
KEY WORDSSS31 SIMD mitochondria inflammation oxidative stress
R.J., M.S., Y.L., and X.D.S. conceived and designed this study. Y.L. carried out experiments. W.J.Y., Y.Y., and L.X.X. collected and analyzed data. W.J.Y. performed statistical analysis. Y.L. and W.J.Y. wrote the manuscript, which was critically reviewed and revised by R.J. and M.S. All authors read and approved the final manuscript.
This investigation was supported by the grants from the Natural Science Foundation of Hubei Province of China (2017CFB674, 2018CFB701), Science and Technology Plan Project of Xiangyang (2014-7-16), the Innovative Team Project (2017-2019) from the Institute of Medicine and Nursing at Hubei University of Medicine, and the Initial Project for Ph.D of Hubei University of Medicine (2015QDJZR03).
Compliance with Ethical Standards
And all the procedures were conducted in accordance with the Guidelines for the Care and Use of Laboratory Animals published by the United States National Institutes of Health (NIH Publication, revised 2011) and were approved by the Ethical Committee for Animal Experimentation of Xiangyang No.1 People’s Hospital.
Conflict of Interest
The authors declare that they have no conflict of interest.
- 5.Okuhara, Y., S. Yokoe, T. Iwasaku, A. Eguchi, K. Nishimura, W. Li, M. Oboshi, Y. Naito, T. Mano, M. Asahi, H. Okamura, T. Masuyama, and S. Hirotani. 2017. Interleukin-18 gene deletion protects against sepsis-induced cardiac dysfunction by inhibiting PP2A activity. International Journal of Cardiology 243: 396–403.CrossRefGoogle Scholar
- 6.Stanzani, G., M.R. Duchen, and M. Singer. 2018. The role of mitochondria in sepsis-induced cardiomyopathy. Biochimica et Biophysica Acta - Molecular Basis of Disease 1865 (4): 759–773.Google Scholar
- 7.Joseph, L.C., D. Kokkinaki, M.C. Valenti, G.J. Kim, E. Barca, D. Tomar, N.E. Hoffman, P. Subramanyam, H.M. Colecraft, M. Hirano, A.J. Ratner, M. Madesh, K. Drosatos, and J.P. Morrow. 2017. Inhibition of NADPH oxidase 2 (NOX2) prevents sepsis-induced cardiomyopathy by improving calcium handling and mitochondrial function. JCI Insight 2 (17).Google Scholar
- 9.Tang, G., H. Yang, J. Chen, M. Shi, L. Ge, X. Ge, and G. Zhu. 2017. Metformin ameliorates sepsis-induced brain injury by inhibiting apoptosis, oxidative stress and neuroinflammation via the PI3K/Akt signaling pathway. Oncotarget 8 (58): 97977–97989.Google Scholar
- 16.Siasos, G., V. Tsigkou, M. Kosmopoulos, D. Theodosiadis, S. Simantiris, N.M. Tagkou, A. Tsimpiktsioglou, P.K. Stampouloglou, E. Oikonomou, K. Mourouzis, A. Philippou, M. Vavuranakis, C. Stefanadis, D. Tousoulis, and A.G. Papavassiliou. 2018. Mitochondria and cardiovascular diseases-from pathophysiology to treatment. Annals Translational Medicine 6 (12): 256.CrossRefGoogle Scholar
- 19.Lu, H.I., F.Y. Lee, C.G. Wallace, P.H. Sung, K.H. Chen, J.J. Sheu, S. Chua, M.S. Tong, T.H. Huang, Y.L. Chen, P.L. Shao, and H.K. Yip. 2017. SS31 therapy effectively protects the heart against transverse aortic constriction-induced hypertrophic cardiomyopathy damage. American Journal of Translational Research 9 (12): 5220–5237.Google Scholar
- 23.Brown, M.A., and W.K. Jones. 2004. NF-kappaB action in sepsis: the innate immune system and the heart. Frontiers in Bioscience 9: 1201–1217.Google Scholar
- 24.Zhang, E., X. Zhao, L. Zhang, N. Li, J. Yan, K. Tu, R. Yan, J. Hu, M. Zhang, D. Sun, and L. Hou. 2019. Minocycline promotes cardiomyocyte mitochondrial autophagy and cardiomyocyte autophagy to prevent sepsis-induced cardiac dysfunction by Akt/mTOR signaling. Apoptosis 24 (3-4): 369–381.CrossRefGoogle Scholar
- 25.Doerrier, C., J.A. García, H. Volt, M.E. Díaz-Casado, M. Luna-Sánchez, B. Fernández-Gil, G. Escames, L.C. López, and D. Acuña-Castroviejo. 2016. Permeabilized myocardial fibers as model to detect mitochondrial dysfunction during sepsis and melatonin effects without disruption of mitochondrial network. Mitochondrion 27 (undefined): 56–63.CrossRefGoogle Scholar
- 26.Zang, Q., D.L. Maass, S.J. Tsai, and J.W. Horton. 2007. Cardiac mitochondrial damage and inflammation responses in sepsis. Surgical Infections 8 (1): 41–54.Google Scholar
- 27.Niu, J., K. Wang, S. Graham, A. Azfer, and P.E. Kolattukudy. 2011. MCP-1-induced protein attenuates endotoxin-induced myocardial dysfunction by suppressing cardiac NF-κB activation via inhibition of IκB kinase activation. Journal of Molecular and Cellular Cardiology 51 (2): 177–186.Google Scholar
- 28.Siegel, M.P., S.E. Kruse, J.M. Percival, J. Goh, C.C. White, H.C. Hopkins, T.J. Kavanagh, H.H. Szeto, P.S. Rabinovitch, and D.J. Marcinek. 2013. Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice. Aging Cell 12 (5): 763–771.CrossRefGoogle Scholar
- 31.Barile, L., V. Lionetti, E. Cervio, M. Matteucci, M. Gherghiceanu, L.M. Popescu, T. Torre, F. Siclari, T. Moccetti, and G. Vassalli. 2014. Extracellular vesicles from human cardiac progenitor cells inhibit cardiomyocyte apoptosis and improve cardiac function after myocardial infarction. Cardiovascular Research 103 (4): 530–541.CrossRefGoogle Scholar
- 32.Li, J., D. Zhang, M. Wiersma, and B. Brundel. 2018. Role of autophagy in proteostasis: friend and foe in cardiac diseases. Cells 7 (12).Google Scholar
- 33.Sun, Y., X. Yao, Q.J. Zhang, M. Zhu, Z.P. Liu, B. Ci, Y. Xie, D. Carlson, B.A. Rothermel, Y. Sun, B. Levine, J.A. Hill, S.E. Wolf, J.P. Minei, and Q.S. Zang. 2018. Beclin-1-dependent autophagy protects the heart during sepsis. Circulation 138 (20): 2247–2262.Google Scholar